Skip to main content
    M

    Madrigal Pharmaceuticals Inc (MDGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $423.96
    -3.43 (-0.80%)

    Market Cap: $9.93B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Madrigal Pharmaceuticals Inc (MDGL) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Madrigal Pharmaceuticals (MDGL) to earn -$2.00 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.59B. Of 19 analysts, 18 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $11.21.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 19 ratings average 1.89, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 95% of the ratings.

    RatingAnalystsShare
    Strong Buy315.8%
    Buy1578.9%
    Hold15.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    19

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 37.7%.

    Fiscal year ending Dec 31, 2026
    -$2.00
    EPS consensus, revenue $1.59B
    Fiscal year ending Dec 31, 2027
    $11.21
    EPS consensus, revenue $2.19B
    Next report
    Feb 17, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.00-$2.00 to -$2.001$1.59B$1.57B to $1.61B17
    Dec 31, 2027$11.21$5.63 to $15.163$2.19B$2.03B to $2.29B18

    Quarterly Estimates

    The EPS consensus falls from $1.14 for the quarter ending Dec 31, 2026 to $0.79 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$1.14-$0.34 to $2.8020$481.19M$431.94M to $528.15M19
    Mar 31, 2027$0.79-$0.39 to $1.972$459.01M$425.14M to $468.40M11

    Estimate Revisions

    No EPS estimate for the 3 periods below was revised in the last 30 days.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202700
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$6.49.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.00-$6.32-$6.49-$6.49-$6.49N/A
    Fiscal year ending Dec 31, 2027$11.21$9.42$9.63$9.63$9.63+16.5%
    Quarter ending Mar 31, 2027$0.79$0.32-$0.76-$0.76-$0.76N/A

    Frequently Asked Questions About MDGL

    What is the MDGL stock forecast?

    Consensus analyst estimates put Madrigal Pharmaceuticals's EPS at -$2.00 for the fiscal year ending Dec 31, 2026, on revenue of $1.59B. The consensus rating from 19 analysts is Buy.

    How do analysts rate MDGL stock?

    Of 19 analysts covering Madrigal Pharmaceuticals, 3 rate it Strong Buy, 15 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from MDGL next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.00, with estimates from -$2.00 to -$2.00 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $11.21, with estimates from $5.63 to $15.16 from 3 analysts.

    What revenue do analysts expect from Madrigal Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.59B, with estimates from $1.57B to $1.61B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.19B, with estimates from $2.03B to $2.29B.

    How many analysts cover MDGL?

    19 analysts rate Madrigal Pharmaceuticals stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.